GANX
Gain Therapeutics Inc
NASDAQ: GANX · HEALTHCARE · BIOTECHNOLOGY
$1.80
-8.60% today
Updated 2026-06-05
Market cap
$72.51M
P/E ratio
—
P/S ratio
255.50x
EPS (TTM)
$-0.58
Dividend yield
—
52W range
$1 – $4
Volume
0.6M
WallStSmart proprietary scores
15
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D7.0
Quality
B+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-5.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$7.20
+300.00%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Altman Z -5.31 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.73M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $140108.00 | $55180.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-17.59M | $-22.27M | $-20.41M | $-20.16M | $-5.61M |
| EPS | — | — | — | — | $-0.58 |
| Free cash flow | $-14.81M | $-18.88M | $-18.90M | $-18.47M | $-4.73M |
| Profit margin | -12,555.13% | -40,354.33% | — | — | — |
Peer comparison
Smart narrative
Gain Therapeutics Inc trades at $1.80. Our Smart Value Score of 15/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -5.31, it sits in the distress.
Frequently asked questions
What is Gain Therapeutics Inc's stock price?
Gain Therapeutics Inc (GANX) trades at $1.80, on a P/S of 255.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Gain Therapeutics Inc overvalued?
Gain Therapeutics Inc carries a Smart Value Score of 15/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Gain Therapeutics Inc (GANX)?
The 12-month analyst consensus target is $7.20, about 300.0% above the current $1.80. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Gain Therapeutics Inc's Altman Z-Score is -5.31, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio255.50x
ROE-151.64%
Beta0.15
50D MA$1.87
200D MA$2.20
Shares out0.04B
Float0.04B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—